3.665USD-2.53%Mkt Cap: 797.88M USDP/E: —Last update: 2026-05-26
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platfo…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap797.88M USD
Enterprise Value474.71M USD
Revenue (TTM)35.54M USD
Gross Profit35.54M USD
Net Income (TTM)-17.37M USD
Revenue/Share0.2210 USD
Last Price3.665 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees69
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.39
PEG—
EV/EBITDA-7.83
EV/Revenue13.36
P/S23.03
P/B2.56
EPS (TTM)-0.52
EPS (Forward)-0.51
52W Range
1.72030% of range8.210
52W High8.210 USD
52W Low1.720 USD
Profitability
Gross Margin100.00%
Oper. Margin-191.77%
EBITDA Margin-170.54%
Profit Margin-22.79%
ROE-17.54%
ROA-11.46%
Growth
Revenue Growth-79.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-75.59M USD
CapEx (TTM)220.00K USD
FCF Margin-125.50%
FCF Yield-5.59%
Net Debt-343.85M USD
Net Debt/EBITDA5.67
Balance Sheet
Debt/Equity0.04
Current Ratio10.38
Quick Ratio10.21
Book Value/Sh1.470 USD
Cash/Share1.593 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)12.30 USD
Target Range6.000 USD – 16.00 USD
# Analysts10
Ownership
Shares Out.217.70M
Float189.46M
Insiders0.59%
Institutions96.25%
Short Interest
Short Ratio7.0d
Short % Float15.50%
Short % Out.13.66%
Shares Short29.74M
Short (prev mo.)22.03M
Technical
SMA 504.363 (-16.0%)
SMA 2003.944 (-7.1%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)3.41M
Avg Vol (10d)3.37M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—